Nichi-Iko Pharmaceutical Co Ltd (4541):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nichi-Iko Pharmaceutical Co Ltd (4541) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5167
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic products. The company eripheral nervous system medicines. The company offers products such as alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium sulfate, betahistine mesilate tablets, calcium gluconate hydrate powder, candesartan cilexetil tablets and diltiazem hydrochloride table, among others. Its products are used for treatments of circulatory, digestive, respiratory, central and peripheral nervous systems. Nichi-Iko offers manufacturing, sales, distribution, export, import and related activities for various types of pharmaceuticals. The company operates in Sapporo, Sendai, Kanto, Tokai-Hokuriku, Osaka, Hiroshima, Fukuoka, and others. Nichi-Iko is headquartered in Toyama, Japan.

Nichi-Iko Pharmaceutical Co Ltd (4541) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nichi-Iko Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12
Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 13
Partnerships 14
Lupin and Nichi-Iko Enter into Partnership Agreement 14
Eisai Enters into Agreement with Nichi-Iko Pharma 15
Nichi-Iko Pharma Enters Into Co-Marketing Agreement With Biolab 16
Equity Offering 17
Sagent Pharma Completes Public Offering Of Shares For US$75.3 Million 17
Acquisition 19
Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 19
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 21
Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 22
Nichi-Iko Pharma Divests 12.6% Stake in Binex for USD50 Million 23
Sagent Pharma Acquires Omega Labs for USD85.3 Million 24
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 26
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 27
Nichi-Iko Pharma Acquires 69% Stake In Yakuhan Pharma 28
Nichi-Iko Pharmaceutical Co Ltd – Key Competitors 29
Nichi-Iko Pharmaceutical Co Ltd – Key Employees 30
Nichi-Iko Pharmaceutical Co Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 32
Recent Developments 33
Strategy And Business Planning 33
Apr 17, 2018: Nichi-Iko Pharmaceutical: Announcement of completion of new production facility by Aprogen Biologics 33
Financial Announcements 34
Feb 07, 2018: Nichi-Iko Pharmaceutical Reports Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2018 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nichi-Iko Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Nichi-Iko Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12
Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 13
Lupin and Nichi-Iko Enter into Partnership Agreement 14
Eisai Enters into Agreement with Nichi-Iko Pharma 15
Nichi-Iko Pharma Enters Into Co-Marketing Agreement With Biolab 16
Sagent Pharma Completes Public Offering Of Shares For US$75.3 Million 17
Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 19
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 21
Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 22
Nichi-Iko Pharma Divests 12.6% Stake in Binex for USD50 Million 23
Sagent Pharma Acquires Omega Labs for USD85.3 Million 24
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 26
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 27
Nichi-Iko Pharma Acquires 69% Stake In Yakuhan Pharma 28
Nichi-Iko Pharmaceutical Co Ltd, Key Competitors 29
Nichi-Iko Pharmaceutical Co Ltd, Key Employees 30
Nichi-Iko Pharmaceutical Co Ltd, Other Locations 31
Nichi-Iko Pharmaceutical Co Ltd, Subsidiaries 32
Nichi-Iko Pharmaceutical Co Ltd, Joint Venture 32

List of Figures
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nichi-Iko Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nichi-Iko Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Nichi-Iko Pharmaceutical Co Ltd (4541):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Doxa AB (DOXA):医療機器:M&Aディール及び事業提携情報
    Summary Doxa AB (Doxa) is a medical device company that develops, manufactures and markets dental bioceramic products. The company’s product includes ceramir crown and bridge, which is dental cement for permanent fixtures including ceramic structures with aluminum oxide or zirconia bodies. Its bioma …
  • Wolters Kluwer N.V. (WKL):企業の財務・戦略的SWOT分析
    Wolters Kluwer N.V. (WKL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • EnBW Energie Baden-Wurttemberg AG (EBK)-石油・ガス分野:企業M&A・提携分析
    Summary EnBW Energie Baden-Wuerttemberg AG (EnBW) is an integrated energy holding company that generates, procures, transmits and supplies electricity; and produces, transports and supplies gas through its subsidiaries. Its generation portfolio includes nuclear, coal, oil, gas, wind, and pumped stor …
  • Globeimmune Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Globeimmune Inc (Globeimmune) is a biopharmaceutical company that develops therapeutic products for treatment of cancer and infectious diseases. The company provides products for infectious disease and oncology. It offers oncology products such as GI-4000, GI-6207 and GI-6301. Globeimmune pr …
  • St. Jude Children’s Research Hospital Inc-製薬・医療分野:企業M&A・提携分析
    Summary St. Jude Children’s Research Hospital Inc (St. Jude) is a healthcare service provider that offers research and clinical care services for children with catastrophic diseases. The hospital provides treatment programs such as brain tumors, leukemia, infectious diseases, immunodeficiency diseas …
  • Reed’s, Inc. (REED):企業の財務・戦略的SWOT分析
    Summary Reed's Inc (Reed) is manufacturer and distribution of non-alcoholic carbonated soft drinks, candies and beverages. The company's product portfolio include Reed's ginger brew, wellness ginger shots, zero sugar, and ginger candies It brews carbonated ginger in various flavors including extra g …
  • PT MultiIntegra:企業の戦略・SWOT・財務情報
    PT MultiIntegra - Strategy, SWOT and Corporate Finance Report Summary PT MultiIntegra - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Blue Energy Ltd (BUL):石油・ガス:M&Aディール及び事業提携情報
    Summary Blue Energy Ltd (BEL) is an oil and gas company that provides exploration and development services. The company provides exploration and production of coal seam gas and conventional oil, and gas resources in Australia. Its projects portfolio includes carpentaria basin, bowen basin, galilee b …
  • Oil and Natural Gas Corporation Limited:戦略・SWOT・企業財務分析
    Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Reata Pharmaceuticals Inc (RETA):製薬・医療:M&Aディール及び事業提携情報
    Summary Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription fa …
  • Society for Worldwide Interbank Financial Telecommunication:企業の戦略的SWOT分析
    Society for Worldwide Interbank Financial Telecommunication - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, k …
  • Zain Group:企業の戦略・SWOT・財務分析
    Zain Group - Strategy, SWOT and Corporate Finance Report Summary Zain Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Elekta AB (EKTA B):医療機器:M&Aディール及び事業提携情報
    Summary Elekta AB (Elekta) is a medical technology company that offers image guided and stereotactic clinical solutions, comprehensive information systems and services for the management of brain disorders and improved cancer care. Its major products include Gamma knife and Extend system; stereotact …
  • Carmell Therapeutics Corp:製品パイプライン分析
    Summary Carmell Therapeutics Corp (Carmell) is a biotechnology company that develops and commercializes bone healing accelerants and tissue healing accelerants. Its pipeline portfolio encompasses adjunctive treatment for long bone fractures in Phase I and Phase II a; and adjunctive treatment for tot …
  • Medifocus Inc (MFS):製薬・医療:M&Aディール及び事業提携情報
    Summary Medifocus Inc (Medifocus) is a medical technology company. The company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate. Its technology platforms includes endo-thermotherapy platform, a catheter-based …
  • Hirose Electric Co Ltd (6806):企業の財務・戦略的SWOT分析
    Hirose Electric Co Ltd (6806) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Black Rock Mining Ltd (BKT):企業の財務・戦略的SWOT分析
    Summary Black Rock Mining Ltd (BRML), formerly Green Rock Energy Ltd, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of graphite properties. It also holds interest in Mahenge Graphite Project which includes high-grade fl …
  • Meta Biomed Co Ltd (059210):企業の製品パイプライン分析2018
    Summary Meta Biomed Co Ltd (Meta Biomed) is a medical device company that develops and manufactures dental materials and equipments. The company provides suture, dental, bone and medical products. It offers various medical products such as endodontic materials, bone restorative materials, implant ma …
  • Royal DSM NV (DSM):製薬・医療:M&Aディール及び事業提携情報
    Summary Royal DSM NV (DSM) is a science-based company with focus on materials, health and nutrition. It produces vitamins, carotenoids, nutritional lipids and other ingredients; specialty plastics; and fiber and resins solutions. DSM develops materials for medical devices and clean energy from crop …
  • Hologic Inc (HOLX):企業の財務・戦略的SWOT分析
    Hologic Inc (HOLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆